130 related articles for article (PubMed ID: 16405564)
1. Cutaneous melanoma: family screening and genetic testing.
Niendorf KB; Tsao H
Dermatol Ther; 2006; 19(1):1-8. PubMed ID: 16405564
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous melanoma and intervention strategies to reduce tumor-related mortality: what we know, what we don't know, and what we think we know that isn't so.
Rhodes AR
Dermatol Ther; 2006; 19(1):50-69. PubMed ID: 16405570
[TBL] [Abstract][Full Text] [Related]
3. Genetic study of familial uveal melanoma: association of uveal and cutaneous melanoma with cutaneous and ocular nevi.
Smith JH; Padnick-Silver L; Newlin A; Rhodes K; Rubinstein WS
Ophthalmology; 2007 Apr; 114(4):774-9. PubMed ID: 17207529
[TBL] [Abstract][Full Text] [Related]
4. Melanoma genetics: a review of genetic factors and clinical phenotypes in familial melanoma.
Pho L; Grossman D; Leachman SA
Curr Opin Oncol; 2006 Mar; 18(2):173-9. PubMed ID: 16462187
[TBL] [Abstract][Full Text] [Related]
5. Contribution of melanocortin-1 receptor gene variants to sporadic cutaneous melanoma risk in a population in central Italy: a case-control study.
Fargnoli MC; Altobelli E; Keller G; Chimenti S; Höfler H; Peris K
Melanoma Res; 2006 Apr; 16(2):175-82. PubMed ID: 16567973
[TBL] [Abstract][Full Text] [Related]
6. Anticipated uptake of genetic testing for familial melanoma in an Australian sample: An exploratory study.
Kasparian NA; Meiser B; Butow PN; Soames Job RF; Mann GJ
Psychooncology; 2007 Jan; 16(1):69-78. PubMed ID: 16874747
[TBL] [Abstract][Full Text] [Related]
7. Management of familial melanoma and nonmelanoma skin cancer syndromes.
Santillan AA; Cherpelis BS; Glass LF; Sondak VK
Surg Oncol Clin N Am; 2009 Jan; 18(1):73-98, viii. PubMed ID: 19056043
[TBL] [Abstract][Full Text] [Related]
8. Genetic testing in familial melanoma: uptake and implications.
de Snoo FA; Riedijk SR; van Mil AM; Bergman W; ter Huurne JA; Timman R; Bertina W; Gruis NA; Vasen HF; van Haeringen A; Breuning MH; Tibben A
Psychooncology; 2008 Aug; 17(8):790-6. PubMed ID: 18613292
[TBL] [Abstract][Full Text] [Related]
9. Multiple primary melanomas in a CDKN2A mutation carrier exposed to ionizing radiation.
Eliason MJ; Hansen CB; Hart M; Porter-Gill P; Chen W; Sturm RA; Bowen G; Florell SR; Harris RM; Cannon-Albright LA; Swinyer L; Leachman SA
Arch Dermatol; 2007 Nov; 143(11):1409-12. PubMed ID: 18025365
[TBL] [Abstract][Full Text] [Related]
10. Predictive testing of the melanocortin 1 receptor for skin cancer and photoaging.
Lynde CW; Sapra S
Skin Therapy Lett; 2010 Jan; 15(1):5-7. PubMed ID: 20066389
[TBL] [Abstract][Full Text] [Related]
11. CDKN2A/p16 genetic test reporting improves early detection intentions and practices in high-risk melanoma families.
Aspinwall LG; Leaf SL; Dola ER; Kohlmann W; Leachman SA
Cancer Epidemiol Biomarkers Prev; 2008 Jun; 17(6):1510-9. PubMed ID: 18559569
[TBL] [Abstract][Full Text] [Related]
12. Comparison between familial and sporadic cutaneous melanoma in Valencia, Spain.
Nagore E; Botella-Estrada R; Garcia-Casado Z; Requena C; Serra-Guillen C; Llombart B; Sanmartin O; Guillen C
J Eur Acad Dermatol Venereol; 2008 Aug; 22(8):931-6. PubMed ID: 18355200
[TBL] [Abstract][Full Text] [Related]
13. A review of genetic mutation in familial Hirschsprung's disease in South Africa: towards genetic counseling.
Moore SW; Zaahl MG
J Pediatr Surg; 2008 Feb; 43(2):325-9. PubMed ID: 18280283
[TBL] [Abstract][Full Text] [Related]
14. Genetics of melanoma susceptibility.
Ghiorzo P; Scarrà GB
Forum (Genova); 2003; 13(2):114-22; quiz 187. PubMed ID: 14732879
[TBL] [Abstract][Full Text] [Related]
15. The prevalence of CDKN2A germ-line mutations and relative risk for cutaneous malignant melanoma: an international population-based study.
Berwick M; Orlow I; Hummer AJ; Armstrong BK; Kricker A; Marrett LD; Millikan RC; Gruber SB; Anton-Culver H; Zanetti R; Gallagher RP; Dwyer T; Rebbeck TR; Kanetsky PA; Busam K; From L; Mujumdar U; Wilcox H; Begg CB;
Cancer Epidemiol Biomarkers Prev; 2006 Aug; 15(8):1520-5. PubMed ID: 16896043
[TBL] [Abstract][Full Text] [Related]
16. The p.G23S CDKN2A founder mutation in high-risk melanoma families from Central Italy.
Gensini F; Sestini R; Piazzini M; Vignoli M; Chiarugi A; Brandani P; Ghiorzo P; Salvini C; Borgognoni L; Palli D; Bianchi-Scarrà G; Carli P; Genuardi M
Melanoma Res; 2007 Dec; 17(6):387-92. PubMed ID: 17992122
[TBL] [Abstract][Full Text] [Related]
17. The simultaneous assessment of constitutional, behavioral, and environmental factors in the development of large nevi.
Cockburn M; Hamilton A; Mack T
Cancer Epidemiol Biomarkers Prev; 2007 Feb; 16(2):200-6. PubMed ID: 17267390
[TBL] [Abstract][Full Text] [Related]
18. Polymorphisms of the neuronal and inducible nitric oxide synthase genes and the risk of cutaneous melanoma: a case-control study.
Li C; Hu Z; Liu Z; Wang LE; Gershenwald JE; Lee JE; Prieto VG; Duvic M; Grimm EA; Wei Q
Cancer; 2007 Apr; 109(8):1570-8. PubMed ID: 17328085
[TBL] [Abstract][Full Text] [Related]
19. High- and average-risk individuals' beliefs about, and perceptions of, malignant melanoma: an Australian perspective.
Kasparian NA; Butow PN; Meiser B; Mann GJ
Psychooncology; 2008 Mar; 17(3):270-9. PubMed ID: 17600854
[TBL] [Abstract][Full Text] [Related]
20. Risk associations of melanoma in a Southern European population: results of a case/control study.
Nikolaou VA; Sypsa V; Stefanaki I; Gogas H; Papadopoulos O; Polydorou D; Plaka M; Tsoutsos D; Dimou A; Mourtzoukou E; Korfitis V; Hatziolou E; Antoniou C; Hatzakis A; Katsambas A; Stratigos AJ
Cancer Causes Control; 2008 Sep; 19(7):671-9. PubMed ID: 18307049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]